
In first open-label phase 3 data from the ADEPT program, KarXT cut hallucination and delusion scores in Alzheimer disease psychosis, with no new safety signals.
Beyond psychosocial implications of anxiety disorders, an array of physiological effects may ensue.
To view a PDF, of this slideshow, click here.




